Compare Snap On Incorporated (SNA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs Spyre Therapeutics Inc. Common Stock — how do they compare? Snap On Incorporated trades at $362.47 (market cap $18.81B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Snap On Incorporated is far larger — about 2.5× Spyre Therapeutics Inc. Common Stock's market cap, and Snap On Incorporated pays a 2.68% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Snap On Incorporated for 38 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SNA | SYRE | |
|---|---|---|
Market Cap | $18.81B | $7.52B |
Volume | 239,235 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $419.31 | $108.92 |
52-Week Low | $328.69 | $22.18 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $18.45B | $6.52B |
Dividend Yield | 2.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-On Incorporated (SNA) trades at $363.67, up 0.46% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 19.6% and ROE of 17.58%, while Q2 2026 earnings beat estimates. Recent news highlights gross margin expansion and institutional trading activity.
The outlook is supported by analyst consensus with a $449 price target and 66.7% buy ratings, but risks include valuation premiums and mixed segment trends. Earnings growth and RCI initiatives remain key catalysts, though integration costs and softer OEM demand pose near-term challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
